Real-world SEMAFOLLOW study to evaluate semaglutide 2.4 mg effectiveness in severe obesity
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
Abstract
SEMAFOLLOW is a real-world study evaluating semaglutide 2.4 mg effectiveness, weight change, and well-being in patients with Grade 3 and complicated obesity.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
